Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer

INTRODUCTION: No predictive clinical or genetic markers have been identified or validated for antiangiogenic agents in lung cancer. We aimed to identify a predictive clinical marker of benefit for nintedanib, an angiokinase inhibitor, using data from two large second-line non-small cell lung cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Gaschler-Markefski, Birgit, Sikken, Patricia, Heymach, John V, Gottfried, Maya, Mellemgaard, Anders, Novello, Silvia, Gann, Claudia-Nanette, Barrueco, José, Reck, Martin, Hanna, Nasser H, Kaiser, Rolf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: ESMO Open 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519785/
https://www.ncbi.nlm.nih.gov/pubmed/28761724
http://dx.doi.org/10.1136/esmoopen-2016-000102

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519785/
https://www.ncbi.nlm.nih.gov/pubmed/28761724
http://dx.doi.org/10.1136/esmoopen-2016-000102

Ejemplares similares